{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:21:10Z","timestamp":1790364070155,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-na\u00efve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular neovascularization (T1 MNV) over a period of 12-month.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective, single-center cohort study was conducted at the Jules Gonin Eye Hospital, Lausanne, Switzerland. Clinical records of treatment-na\u00efve and non-responder switch patients presenting T1 MNV secondary to neovascular age-related macular degeneration (nAMD) from September 2022 to March 2023 were reviewed. Patients received a loading dose of three monthly Faricimab injections followed by a treat-and-extend (T&amp;E) regimen. Multimodal imaging, including structural OCT and AI-assisted analysis, was used to quantify PED volumes and related fluid biomarkers at baseline, 3-month, 6-month, and 12-month follow-up. Statistical analyses included linear mixed models to evaluate differences and trends in intraretinal (IRF), subretinal fluid (SRF) and PED volumes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>65 eyes of 65 patients were enrolled (female: 70.7%; mean age\u2009=\u200980.7yrs, SD\u2009=\u20096.9yrs). 80% had received anti-VEGF treatment (Switch group) and 20% were treatment-Na\u00efve at baseline. At 12 months, intravitreal treatments were more frequent in the Switch group (mean number\u2009=\u20098.3 vs. 6.0; <jats:italic>p<\/jats:italic>\u2009=\u20090.009). BCVA improved at the 12-month follow-up in Na\u00efve eyes (+\u20096.9 ETDRS letters from baseline, <jats:italic>p<\/jats:italic>\u2009=\u20090.053) and was maintained in Switch eyes. No cases of intraocular inflammation were observed. Significant reduction in SRF and IRF volumes were noted in both groups. A significant reduction in PED volume was observed over the follow-up period in both groups (mean slope = -206 nL, 95%CL = -273\/-138; <jats:italic>p<\/jats:italic>-value\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Intravitreal Faricimab significantly reduced PED volumes in both treatment-Na\u00efve and non-responder Switch patients over 12 months. The study highlights Faricimab\u2019s potential as an effective treatment option for T1 MNV in nAMD, offering significant improvements in PED volume and related fluid biomarkers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-025-00629-w","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:30:05Z","timestamp":1736433005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Na\u00efve and switch eyes"],"prefix":"10.1186","volume":"11","author":[{"given":"Jennifer","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"629_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ajo.2014.07.006","volume":"158","author":"JJ Jung","year":"2014","unstructured":"Jung JJ, Chen CY, Mrejen S, Gallego-Pinazo R, Xu L, Marsiglia M, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol. 2014;158:769\u2013e7792.","journal-title":"Am J Ophthalmol"},{"key":"629_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"629_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.survophthal.2023.10.013","volume":"69","author":"A Feo","year":"2024","unstructured":"Feo A, Stradiotto E, Sacconi R, Menean M, Querques G, Romano MR. Subretinal hyperreflective material in retinal and chorioretinal disorders: a comprehensive review. Surv Ophthalmol. 2024;69:362\u201377.","journal-title":"Surv Ophthalmol"},{"key":"629_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3109\/08820538.2011.570850","volume":"26","author":"K Pepple","year":"2011","unstructured":"Pepple K, Mruthyunjaya P. Retinal pigment epithelial detachments in age-related macular degeneration: classification and therapeutic options. Semin Ophthalmol. 2011;26:198\u2013208.","journal-title":"Semin Ophthalmol"},{"key":"629_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ajo.2013.06.024","volume":"156","author":"A Nagiel","year":"2013","unstructured":"Nagiel A, Freund KB, Spaide RF, Munch IC, Larsen M, Sarraf D. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography. Am J Ophthalmol. 2013;156:981\u2013e9882.","journal-title":"Am J Ophthalmol"},{"key":"629_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: classification of Atrophy Report 3. Ophthalmology. 2018;125:537\u201348.","journal-title":"Ophthalmology"},{"key":"629_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajo.2022.09.008","volume":"246","author":"KX Cheong","year":"2023","unstructured":"Cheong KX, Cheung CMG, Teo KYC. Review of fibrosis in Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2023;246:192\u2013222.","journal-title":"Am J Ophthalmol"},{"key":"629_CR8","doi-asserted-by":"crossref","unstructured":"Forte P, Fontana V, Muzio J, Di Cello L, Corazza P, Rosa R et al. Predictors of 24-month onset of macular fibrosis in type 3 macular neovascularisation. Br J Ophthalmol. 2024;bjo-2023-324713.","DOI":"10.1136\/bjo-2023-324713"},{"key":"629_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2016.03.002","volume":"787","author":"CM Eandi","year":"2016","unstructured":"Eandi CM, Alovisi C, De Sanctis U, Grignolo FM. Treatment for neovascular age related macular degeneration: the state of the art. Eur J Pharmacol. 2016;787:78\u201383.","journal-title":"Eur J Pharmacol"},{"key":"629_CR10","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1097\/IAE.0000000000002195","volume":"38","author":"AM Khanani","year":"2018","unstructured":"Khanani AM, Eichenbaum D, Schlottmann PG, Tuomi L, Sarraf D. Optimal management of pigment epithelial detachments in eyes with neovascular age-related macular degeneration. Retina. 2018;38:2103\u201317.","journal-title":"Retina"},{"key":"629_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"629_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","volume":"30","author":"M Nicol\u00f2","year":"2021","unstructured":"Nicol\u00f2 M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30:193\u2013200.","journal-title":"Expert Opin Investig Drugs"},{"key":"629_CR13","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik J-F, et al. Tenaya and Lucerne: Rationale and Design for the phase 3 clinical trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2021;1:100076.","journal-title":"Ophthalmol Sci"},{"issue":"23","key":"629_CR14","first-page":"00623","volume":"S2468\u20136530","author":"R Raimondi","year":"2023","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, et al. Outcomes of treatment-resistant neovascular age-related Macular Degeneration switched from Aflibercept to Faricimab. Ophthalmol Retina. 2023;S2468\u20136530(23):00623\u20131.","journal-title":"Ophthalmol Retina"},{"key":"629_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","volume":"8","author":"A Szigiato","year":"2024","unstructured":"Szigiato A, Mohan N, Talcott KE, Mammo DA, Babiuch AS, Kaiser PK, et al. Short-term outcomes of Faricimab in patients with neovascular age-related Macular Degeneration on prior Anti-VEGF therapy. Ophthalmol Retina. 2024;8:10\u20137.","journal-title":"Ophthalmol Retina"},{"key":"629_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","volume":"8","author":"SA Pandit","year":"2024","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, et al. Clinical outcomes of Faricimab in patients with previously treated neovascular age-related Macular Degeneration. Ophthalmol Retina. 2024;8:360\u20136.","journal-title":"Ophthalmol Retina"},{"key":"629_CR17","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1177\/15353702211031547","volume":"246","author":"K Romond","year":"2021","unstructured":"Romond K, Alam M, Kravets S, de Sisternes L, Leng T, Lim JI, et al. Imaging and artificial intelligence for progression of age-related macular degeneration. Exp Biol Med (Maywood). 2021;246:2159\u201369.","journal-title":"Exp Biol Med (Maywood)"},{"key":"629_CR18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.survophthal.2023.04.001","volume":"68","author":"AC Oganov","year":"2023","unstructured":"Oganov AC, Seddon I, Jabbehdari S, Uner OE, Fonoudi H, Yazdanpanah G, et al. Artificial intelligence in retinal image analysis: development, advances, and challenges. Surv Ophthalmol. 2023;68:905\u201319.","journal-title":"Surv Ophthalmol"},{"key":"629_CR19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW trials. Ophthalmology. 2016;123:1521\u20139.","journal-title":"Ophthalmology"},{"key":"629_CR20","doi-asserted-by":"publisher","first-page":"NP123","DOI":"10.1177\/11206721231185903","volume":"34","author":"P Forte","year":"2024","unstructured":"Forte P, Ferro Desideri L, Manocchio R, Corazza P, Traverso CE, Nicol\u00f2 M. Prechoroidal Cleft Regression after switch to Intravitreal Brolucizumab. Eur J Ophthalmol. 2024;34:NP123\u20136.","journal-title":"Eur J Ophthalmol"},{"key":"629_CR21","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond). 2023;37:3282\u20139.","journal-title":"Eye (Lond)"},{"key":"629_CR22","doi-asserted-by":"crossref","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024.","DOI":"10.1007\/s00417-024-06421-0"},{"key":"629_CR23","doi-asserted-by":"crossref","unstructured":"Veritti D, Sarao V, Gonfiantini M, Rubinato L, Lanzetta P. Faricimab in Neovascular AMD Complicated by Pigment Epithelium Detachment: An AI-Assisted Evaluation of Early Morphological Changes. Ophthalmol Ther. 2024.","DOI":"10.1007\/s40123-024-01005-x"},{"key":"629_CR24","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559\u201369.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"629_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40942-024-00549-1","volume":"10","author":"V Mares","year":"2024","unstructured":"Mares V, Nehemy MB, Bogunovic H, Frank S, Reiter GS, Schmidt-Erfurth U. AI-based support for optical coherence tomography in age-related macular degeneration. Int J Retina Vitreous. 2024;10:31.","journal-title":"Int J Retina Vitreous"},{"key":"629_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","volume":"125","author":"T Schlegl","year":"2018","unstructured":"Schlegl T, Waldstein SM, Bogunovic H, Endstra\u00dfer F, Sadeghipour A, Philip A-M, et al. Fully Automated Detection and Quantification of Macular Fluid in OCT using deep learning. Ophthalmology. 2018;125:549\u201358.","journal-title":"Ophthalmology"},{"key":"629_CR27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth U, Vogl W-D, Jampol LM, Bogunovi\u0107 H. Application of automated quantification of Fluid volumes to Anti\u2013VEGF therapy of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:1211\u20139.","journal-title":"Ophthalmology"},{"key":"629_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ophtha.2020.09.025","volume":"128","author":"G Moraes","year":"2021","unstructured":"Moraes G, Fu DJ, Wilson M, Khalid H, Wagner SK, Korot E, et al. Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration using deep learning. Ophthalmology. 2021;128:693\u2013705.","journal-title":"Ophthalmology"},{"key":"629_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/bjo-2022-323014","volume":"108","author":"V Mares","year":"2024","unstructured":"Mares V, Schmidt-Erfurth UM, Leingang O, Fuchs P, Nehemy MB, Bogunovic H, et al. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. Br J Ophthalmol. 2024;108:971\u20137.","journal-title":"Br J Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00629-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00629-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00629-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:44:16Z","timestamp":1736433856000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00629-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00629-w","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved locally by the ethics committee of Canton Vaud (Switzerland) CERVD: 2017\u2009\u2212\u200900493. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}